Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development. Its current business is organized around genomics, data, and artificial intelligence applications, with products spanning next-generation sequencing, molecular profiling, clinical decision support, and software-based diagnostic tools. Tempus AI serves healthcare providers, researchers, and pharmaceutical and biotechnology companies across oncology and other clinical areas, including cardiology, neuropsychiatry, infectious disease, and radiology. The stock represents ownership in a company positioned at the intersection of healthcare, data analytics, and diagnostic innovation.
Omsætning og resultat (USD)
Gns. kursmål: $72,72

Natera Partners With TransCode to Advance Colorectal Cancer Trial
Zacks Investment Research · 21. okt. 2026

Here's How Tempus AI Demonstrates Improving Operating Leverage
Zacks Investment Research · 19. okt. 2026

Tempus AI Expands Strategic Collaborations to Drive Future Growth
Zacks Investment Research · 12. okt. 2026
Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development. Its current business is organized around genomics, data, and artificial intelligence applications, with products spanning next-generation sequencing, molecular profiling, clinical decision support, and software-based diagnostic tools. Tempus AI serves healthcare providers, researchers, and pharmaceutical and biotechnology companies across oncology and other clinical areas, including cardiology, neuropsychiatry, infectious disease, and radiology. The stock represents ownership in a company positioned at the intersection of healthcare, data analytics, and diagnostic innovation.
Omsætning og resultat (USD)
Gns. kursmål: $72,72

Natera Partners With TransCode to Advance Colorectal Cancer Trial
Zacks Investment Research · 21. okt. 2026

Here's How Tempus AI Demonstrates Improving Operating Leverage
Zacks Investment Research · 19. okt. 2026

Tempus AI Expands Strategic Collaborations to Drive Future Growth
Zacks Investment Research · 12. okt. 2026